A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

Launched by RASCAL THERAPEUTICS, INC. · Dec 16, 2020

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called RSC-1255 for patients with advanced solid tumors, such as lung, colon, glioblastoma, and pancreatic cancers. It is specifically for individuals who have already tried other therapies without success, or who cannot tolerate existing treatments that are usually effective. The trial is divided into two parts: the first part will determine the right dose of the medication, and the second part will look at how safe and effective RSC-1255 is for treating these cancers.

To be eligible for this trial, participants must be at least 18 years old and have a confirmed diagnosis of advanced cancer that has either worsened despite treatment or has not responded to standard therapies. They should also have measurable tumors that can be assessed through medical imaging or tests. However, people currently receiving cancer treatment or with significant health issues affecting major organs may not qualify. If you join the trial, you can expect close monitoring and regular check-ups to assess your response to the treatment and its safety. This trial aims to offer hope for those who have limited options left.

Gender

ALL

Eligibility criteria

• Inclusion Criteria (Key Factors):
• 1. Has pathologically confirmed advanced or metastatic malignancy characterized by one or more of the following:
• • Participant is intolerant of existing therapy(ies) known to provide clinical benefit for their condition
• • Malignancy is refractory to existing therapy(ies) known to potentially provide clinical benefit
• • Malignancy has progressed on standard therapy
• • 2. Has evaluable or measurable tumor(s) in dose-escalation by standard radiological and/or laboratory assessments as applicable to their malignancy.
• • 3. Has adequate performance status (PS): Eastern Co-operative Oncology Group (ECOG).
• • 4. Is age ≥ 18 years.
• Exclusion Criteria (Key Factors):
• • 1. Participants receiving cancer therapy at the time of enrollment.
• • 2. Any clinically significant disease or condition affecting a major organ system.
• • 3. Significant cardiovascular disease or electrocardiogram (ECG) abnormalities.
• • 4. Known Gilbert's disease.
• • 5. Has had a previous (within 2 years) or has a current malignancy other than the target cancer.